Skip to main content

Polymeropoulos Mihael Hristos's Form 4 filing

Vanda Pharmaceuticals Inc. (VNDA) · filed Dec 7, 2022

Accession no.
0001209191-22-060227
Filed
Dec 7, 2022
Trade date
Dec 5-6, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.02M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Polymeropoulos Mihael HristosCIK 0001355537Director, Officer (President and CEO), Other: Chairman of the Board

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 5, 2022Common StockMOption exerciseAcquired+74,635$3.12+$232,861.21,427,401Direct
Dec 5, 2022Common StockSSaleDisposed−47,650$10.62−$506,0431,379,751Direct
Dec 6, 2022Common StockMOption exerciseAcquired+75,365$3.12+$235,138.81,455,116Direct
Dec 6, 2022Common StockSSaleDisposed−48,250$10.61−$511,932.51,406,866Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 5, 2022Common StockMOption exerciseDisposed−74,635$0.00$075,365Direct
Dec 6, 2022Common StockMOption exerciseDisposed−75,635$0.00$00Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)